Lipid-Based Drug Delivery Systems in Viral Hepatitis Treatment

Viral hepatitis remains a significant global health concern, affecting millions worldwide and posing challenges in treatment efficacy and drug delivery. At Creative Biolabs, we recognize the critical need for innovative solutions in this field and are dedicated to advancing the application of lipid-based drug delivery systems to enhance the treatment of viral hepatitis. Our integrated formulation design, analytical capabilities, and diverse in vitro and in vivo models enable us to support your research at every stage, from concept to reality.

Background of Viral Hepatitis

Viral hepatitis constitutes a significant global health burden, stemming from infections caused by a diverse group of hepatotropic viruses. The main types of viral hepatitis are hepatitis A, B, C, D, and E (HAV, HBV, HCV, HDV, HEV), each with distinct transmission routes, clinical courses, and epidemiological profiles. While some types result in acute, self-limiting infections, chronic forms, particularly Hepatitis B (HBV) and Hepatitis C (HCV), are major drivers of progressive liver diseases. These chronic infections can lead to severe pathologies including hepatic fibrosis, cirrhosis, and ultimately, hepatocellular carcinoma (HCC) or liver failure, posing immense challenges to global public health.

Challenges in Hepatitis Therapies

Treatment Strategies for Viral Hepatitis

The evolution of treatment strategies for viral hepatitis reflects a concerted effort to combat these complex and often chronic infections more effectively. From broad-spectrum approaches to highly targeted interventions and gene-editing technologies, the therapeutic landscape is continuously advancing to achieve higher cure rates and minimize adverse effects.

• Antiviral Therapies: Antiviral drugs such as host-targeted antivirals (HTAs) and direct-acting antivirals (DAAs) (e.g., NS3/4A protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors) are widely used to suppress viral replication.
• Gene Editing: This revolutionary technology offers the potential for a functional cure by precisely targeting and disrupting viral DNA (e.g., HBV's persistent cccDNA) or viral RNA, or by modifying host factors essential for viral replication. It aims to eliminate the viral reservoir and prevent relapse, though challenges related to specificity, delivery, and resistance are under active research.
• Vaccination: Vaccines for hepatitis A and B have significantly reduced the incidence of these diseases.

Fig. 2 Gene editing technology for theragnostic of viral hepatitis and HCC.^2,4

However, many of these therapies face challenges such as off-target effects and safety concerns. Antiviral medications may lead to drug resistance and side effects due to non-specific targeting. To address these issues, lipid-based drug delivery systems offer a valuable solution. By encapsulating therapeutic agents within lipid nanoparticles(LNPs) and liposomes, we can enhance targeted delivery to liver cells, reduce systemic exposure, and minimize off-target effects. This approach not only improves the safety profile of treatments but also enhances their efficacy by ensuring higher concentrations of active drugs at the site of infection.

How Creative Biolabs' Lipid-Based Drug Delivery Systems Can Assist Your Project

Creative Biolabs' lipid-based drug delivery systems are engineered to overcome the inherent limitations of traditional drug formulations, particularly for complex therapeutic molecules and challenging disease targets like viral hepatitis. Our customized delivery systems provide a versatile platform for encapsulating a wide range of antivirals drugs, including small molecules, protein/peptide, nucleic acids (e.g., siRNA, mRNA) and vaccines, ensuring their stable and effective delivery.

Workflow for Lipid-Based Drug Delivery Systems Development for Viral Hepatitis

At Creative Biolabs, we stand at the forefront of innovation in combining lipid-based drug delivery systems with viral hepatitis treatment. Our functionalized delivery system development platform supports antibody, peptide, aptamer, and other ligand-based liver-targeted delivery. We are committed to helping you advance your research and make a significant impact in the fight against viral hepatitis. Contact us today to learn how our lipid-based drug delivery systems can elevate your research and drive progress in this critical area.

Related Services

Resources

For Research Use Only. Not For Clinical Use